SCUBE1: A Potential Drug Target and Biomarker (G80274)

Target Name: SCUBE1

NCBI ID: G80274

SCUBE1

Other Name(s): Signal peptide-CUB domain-EGF-related 1 | signal peptide, CUB domain, EGF-like 1 | signal peptide, CUB domain and EGF like domain containing 1 | SCUB1_HUMAN | Signal peptide, CUB and EGF-like domain-containing protein 1 | Signal peptide, CUB domain and EGF like domain containing 1 | signal peptide-CUB domain-EGF-related 1

SCUBE1: A Potential Drug Target and Biomarker

Scuba1 (Signal peptide-CUB domain-EGF-related 1) is a protein that has been identified as a potential drug target and biomarker. It is a 21-kDa protein that is expressed in various tissues and cell types, including brain, heart, liver, and pancreas. SCUBA1 has been shown to play a role in the regulation of cell proliferation, differentiation, and survival.

The Signal Peptide-CUB domain-EGF-related 1 (SP-CUB-ERG) gene is a gene that encodes a protein with a signal peptide domain and a CUB domain. The signal peptide domain is responsible for the initiation of the protein and is involved in the formation of a protein-peptide complex. The CUB domain is a unique protein domain that is found in a variety of proteins, including the SPOP (signal peptide-type) protein. The CUB domain is involved in the formation of a covalent complex with the EGF (E growth factor) receptor.

SP-CUB-ERG has been shown to play a role in the regulation of cell proliferation and survival. It has been shown to inhibit the activity of the EGF receptor, which is involved in cell growth, differentiation, and survival. In addition, SP-CUB-ERG has been shown to promote the formation of cell-cell adhesion, which is important for the regulation of cell behavior and the development of tissues.

The Potential Role of SCUBA1 as a Drug Target

The inhibition of SP-CUB-ERG by SCUBA1 has been shown to have potential therapeutic implications. By inhibiting the activity of SP-CUB-ERG, SCUBA1 has been shown to inhibit the growth and survival of cancer cells. This suggests that SCUBA1 may be an effective target for cancer therapies.

In addition, the regulation of cell proliferation and differentiation is a critical process in the development and maintenance of tissues and organs. The inhibition of SP-CUB-ERG by SCUBA1 has been shown to disrupt the regulation of cell proliferation and survival, which may have implications for the development of diseases such as cancer.

The Potential Role of SCUBA1 as a Biomarker

SP-CUB-ERG is a protein that is expressed in various tissues and cell types, including brain, heart, liver, and pancreas. The expression of SP-CUB-ERG has been shown to be associated with the development and progression of certain diseases, including cancer.

In addition, the regulation of cell proliferation and survival is a critical process in the development and maintenance of tissues and organs. The inhibition of SP-CUB-ERG by SCUBA1 has been shown to disrupt the regulation of cell proliferation and survival, which may have implications for the development of diseases such as cancer.

Conclusion

In conclusion, SCUBA1 is a protein that has been identified as a potential drug target and biomarker. The inhibition of SP-CUB-ERG by SCUBA1 has been shown to have therapeutic implications for the development and treatment of cancer. Further research is needed to fully understand the role of SCUBA1 as a drug target and biomarker.

Protein Name: Signal Peptide, CUB Domain And EGF Like Domain Containing 1

Functions: Could function as an adhesive molecule and its matrix bound and soluble fragments may play a critical role in vascular biology

The "SCUBE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCUBE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets